Iron Acquisition Pathways as Targets for Antitubercular Drugs.
Tuberculosis nowadays ranks as the second leading cause of death from an infectious disease worldwide. In the last twenty years, this disease has again started to spread mainly for the appearance of multi-drug resistant forms. Therefore, new targets are needed to address the growing emergence of bacterial resistance and for antitubercular drug development. Efficient iron acquisition is crucial for the pathogenesis of Mycobacterium tuberculosis, because it serves as cofactor in many essential biological processes, including DNA biosynthesis and cellular respiration. Bacteria acquire iron chelating non-heme iron from the host using the siderophore mycobactins and carboxymycobactins and by the uptake of heme iron released by damaged red blood cells, through several acquisition systems. Drug discovery focused its efforts on the inhibition of MbtI and MbtA, which are are two enzymes involved in the mycobactin biosynthetic pathway. In particular, MbtI inhibitors have been studied in vitro, while MbtA inhibitors showed activity also in infected mice. Another class of compounds, MmpL3 inhibitors, showed antitubercular activity in vitro and in vivo, but their mechanism of action seems to be off-target. Some compounds inhibiting 4'-phosphopantetheinyl transferase were discovered but not tested on in vivo assays. The available data reported in this study based on inhibitors and gene deletion studies, suggest that targeting iron acquisition systems could be considered a promising antitubercular strategy. Due to their redundancy, the relative importance of each pathway for Mycobacterium tuberculosis survival has still to be determined. Thus, in vivo studies with new, potent and specific inhibitors are needed to highlight target selection.
Fiorella
F
Meneghetti
Dipartimento di Scienze Farmaceutiche, Faculty of Scienze del Farmaco, via L. Mangiagalli, 25-20133 Milano, Italy. stefania.villa@unimi.it.
Stefania
S
Villa
Arianna
A
Gelain
Daniela
D
Barlocco
Laurent Roberto
LR
Chiarelli
Maria Rosalia
MR
Pasca
Luca
L
Costantino
D000818:Animals; D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008025:Ligases / Q000737:chemistry / Q000378:metabolism; D008565:Membrane Proteins / Q000737:chemistry / Q000378:metabolism; D062105:Molecular Docking Simulation; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000378:metabolism; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
D000995:Antitubercular Agents; D001426:Bacterial Proteins; D008565:Membrane Proteins; D007501:Iron; D008025:Ligases; C526815:salicyl-AMP ligase, Mycobacterium tuberculosis